The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis

Table 2 The main features of 11 included studies in prognostic meta-analysis

First author	Year	Country	Ethnicity	Case	Outcome	HR (95%CIs)	P value
Mitch Raponi [28]	2009	America	Caucasian	54	OS	2.30 (1.00–5.60)	0.060
Motonobu Saito (1) [29]	2011	Japan	Caucasian	89	PFS	2.37 (1.27–4.42)	0.006
Motonobu Saito (2) [29]	2011	Japan	Caucasian	37	PFS	1.60 (0.73–3.52)	0.245
Motonobu Saito (3) [29]	2011	Japan	Asian	191	PFS	1.33 (0.77–2.29)	0.309
Yi Gao [30]	2014	China	Asian	162	OS	2.31 (1.48–3.61)	< 0.001
Johannes Voortman [31]	2010	France	Caucasian	637	OS	0.91 (0.72–1.13)	0.390
Tom Donnem (1) [32]	2011	Norway	Caucasian	191 (SCC)	PFS	0.45 (0.21–0.96)	0.039
Tom Donnem (2) [32]	2011	Norway	Caucasian	95 (AC)	PFS	1.87 (1.01–3.48)	0.047
Ce´ line Sanfiorenzo [33]	2013	France	Caucasian	52	DFS	0.94 (0.15–5.74)	0.008
Xinying Xue (1) [34]	2016	China	Asian	80	OS	0.52 (0.24–1.14)	0.045
Xinying Xue (2) [34]	2016	China	Asian	80	DFS	0.83 (0.30–2.31)	0.054

OS: overall survival; DFS: disease free survival; PFS: progression-free survival;SCC:squamous cell carcinoma;AC:Adenocarcinoma

ISSN: 1471-2407